Drugs that could bring health to tens of thousands of kidney patients, cure osteoporosis and advance the battle against cancer were featured Wednesday on the second day of MichBio Expo, the annual meeting of the state’s biosciences business community.
A 49-year-old Southfield man was the first patient at Beaumont Hospital, Royal Oak to receive a kidney and liver through Beaumont’s new multi-organ transplant program on April 19.
With the prospect of a three to five-year wait for a transplant kidney, 35-year-old kidney disease sufferer Jeff Kurze and his wife, Roxy, of Warren, turned to Facebook. Much to their surprise, Ricky Cisco, 25, of Royal Oak, replied to Roxy’s posting expressing interest in being a donor for her husband. After subsequent testing he was declared a match. The transplant took place on March 30 at Beaumont Hospital in Royal Oak.
Kalamazoo-based NephRx Corp. announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that […]
Kalamazoo-based NephRx Corp. announced that the United States Food and Drug Administration has granted orphan drug designation to its product NX001 for the prevention of delayed graft function in kidney transplant recipients. NX001 is a […]